Amyloidosis Forum Scientific Workshop
January 22nd, 2021
11:00am-3:30pm EST
Considerations for Novel Endpoint Development in AL Amyloidosis
Following the most recent Amyloidosis Forum held on October 15, 2020 (archived here), several different organ-specific working groups have formed through the ARC/FDA public private partnership to facilitate the development of a composite or multidomain endpoint for AL amyloidosis. The objective of each working group has been to identify and prioritize the most important organ-specific endpoints that could be considered as components to a composite or multidomain endpoint in AL amyloidosis. This Amyloidosis Forum meeting will bring together each of these organ-specific working groups along with independent and regulatory statisticians to discuss the output of each working group and potential components to a composite or multidomain endpoint in AL amyloidosis.